Brain Volume Changes After Withdrawal of Atypical Antipsychotics in Patients With First-Episode Schizophrenia

Geartsje Boonstra, MD, MSc,*† Neeltje E.M. van Haren, PhD,* Hugo G. Schnack, PhD,* Wiepke Cahn, MD, PhD,* Huibert Burger, MD, PhD,†‡ Maria Boersma, MSc,* Bart de Kroon, MSc,* Diederick E. Grobbee, MD, PhD,† Hilleke E. Hulshoff Pol, PhD,* and René S. Kahn, MD, PhD*

Abstract: The influence of atypical antipsychotic medication on brain morphology in schizophrenia may confound interpretation of brain changes over time. We aimed to assess the effect of discontinuation of atypical antipsychotic medication on change in brain volume in patients. Sixteen remitted, stable patients with first-episode schizophrenia, schizoaffective or schizotypal disorder and 20 healthy controls were included. Two magnetic resonance imaging brain scans were obtained from all subjects with a 1-year interval. The patients either discontinued (n = 8) their atypical antipsychotic medication (olanzapine, risperidone, or quetiapine) or did not (n = 8) discontinue during the follow-up period. Intracranial volume and volumes of total brain, cerebral gray and white matter, cerebellum, third and lateral ventricle, nucleus caudatus, nucleus accumbens, and putamen were obtained. Multiple linear regression analyses were used to assess main effects for group (patient-control) and discontinuation (yes-no) for brain volume (change) while correcting for age, sex, and intracranial volume. Decrease in cerebral gray matter and caudate nucleus volume over time was significantly more pronounced in patients relative to controls. Our data suggest decreases in the nucleus accumbens and putamen volumes during the interval in patients who discontinued antipsychotic medication, whereas increases were found in patients who continued their antipsychotics. We confirmed earlier findings of excessive gray matter volume decrements in patients with schizophrenia compared with normal controls. We found evidence suggestive of decreasing volumes of the putamen and nucleus accumbens over time after discontinuation of medication. This might suggest that discontinuation reverses effects of atypical medication.

Key Words: antipsychotic agents, magnetic resonance imaging, schizophrenia, follow-up studies, withholding treatment

(J Clin Psychopharmacol 2011;31: 146–153)
or persecution) of the Positive and Negative Syndrome Scale (PANSS) were included. Exclusion criteria were medication noncompliance during the past year, use of mood stabilizers, severe neurological illness, current suicidal ideation, or a history of a serious suicide attempt. Duration of remission, suicidal ideation, and compliance were assessed by interviewing patients and their treating physician. Of the included patients, brain MR images were acquired at baseline (T0) and at 12 months’ follow-up (T12) or, if possible, at relapse before T12 and before medication restart. To assess the influence of discontinuation of atypical antipsychotics on brain volume change (corrected for time interval: \[T0 - T12\]), the included patients were divided in 2 subgroups: patients who tapered (in 6–12 weeks) and discontinued antipsychotic treatment \((n = 8)\) and patients who continued antipsychotics \((n = 8)\) between T0 and T12. A proportion of the participating patients \((n = 10)\) was selected from a randomized trial investigating the effect of discontinuation versus continuation of antipsychotics on relapse risk (First author, accepted for publication). Half of the patients in this study were originally randomized to continuation \((n = 4)\) or discontinuation \((n = 4)\) and remained in that group. Two patients in the discontinuation group were originally randomized to continuation but tapered and discontinued after 6 months in the study. The remainder of the patients \((n = 6)\) chose to continue or discontinue their antipsychotics. All subjects participating in this study were on atypical antipsychotic medication at inclusion. The type of drug had been determined by the treating physician, and not the researcher, and remained the responsibility of the treating physician during the study. In retrospect, none of the patients changed their type of antipsychotic medication during the current study. During follow-up, the patients were evaluated every 2 months by a trained researcher, with extra visits in case of impending relapse. In each visit, the PANSS was administered and medication status was assessed. Haloperidol dose equivalents (HEQ) for quantification of antipsychotic exposure were calculated using patient charts as follows (ratio haloperidol–other antipsychotic): risperidone, 1:1; olanzapine, 1:2.5; quetiapine 1:100.\(^1\)

In addition, 20 controls were included and scanned twice with an interval of an average of 1 year. The controls were group matched for age and sex to the patients. The control sample has been described previously. Baseline characteristics are shown in Table 1. The controls had no mental (history) or physical illness at both baseline and follow-up measurements.

### MRI Data Acquisition
Magnetic resonance images (MRIs) were acquired using a 1.5-T Philips NT scanner. A T1-weighted 3-dimensional (3D) fast field echo (echo time [TE], 4.6 milliseconds; repetition time [TR], 30 milliseconds; flip angle, 30 degrees; field of view [FOV], 256/80% mm) with 160 to 180 contiguous coronal 1.2-mm slices, and a T2-weighted dual echo turbo spin echo (TE1, 14 milliseconds; TE2, 80 milliseconds; TR, 6350 milliseconds; flip angle, 90 degrees; FOV, 256/80% mm) with 120 contiguous coronal 1.6-mm slices of the whole head were used for the quantitative measurements. In addition, a T2-weighted DE-TSE (Dual

| TABLE 1. Baseline Characteristics of Normal Controls (NCS), All Patients (PTS), Patients Who Were Medication-Free at Follow-Up (OFF), and Patients on Medication at Follow-Up (ON) |
|-----------------|-----------------|---------|---------|---------|---------|---------|
| Variables, N or Mean (SD) | NCS | PTS | P | PTS OFF | PTS ON | P |
| Sex, male/female | 15/5 | 12/4 | n.s. | 6/2 | 6/2 | n.s. |
| Age, y | 27.97 (5.63) | 28.8 (6.9) | n.s. | 27.97 (8.24) | 29.56 (5.72) | n.s. |
| Handedness (right/left/both hands) | 16/4/0 | 13/2/1 | n.s. | 7/1/0 | 6/1/1 | n.s. |
| Patients’ level of education, y | 14.40 (2.30) | 12.94 (2.49) | n.s. | 13.75 (2.12) | 12.13 (2.70) | n.s. |
| Parental level of education, y | 12.60 (2.14) | 12.13 (3.00) | n.s. | 13.93 (1.84) | 10.56 (3.02) | 0.02 |
| Diagnosis: schizophrenia/schizoaffective/schizofreniform | 8/6/2 | 4/3/1 | n.s. | 4/3/1 | n.s. |
| Scan interval, wk | 53.76 (5.09) | 55.63 (6.11) | n.s. | 57.27 (8.55) | 54.00 (8.04) | n.s. |
| Age at onset of illness, y | 25.49 (7.04) | 25.84 (8.16) | n.s. | 25.84 (8.16) | 25.14 (6.27) | n.s. |
| Antipsychotic taken during interval | 11/3 | 6/2 | n.s. | 6/2 | 5/1/2 | n.s. |
| olanzapine/risperidone/quetiapine | | | | | | |
| Duration of psychosis before remission, y | 1.19 (1.87) | 0.96 (1.26) | n.s. | 0.96 (1.26) | 1.42 (2.41) | 0.02 |
| Dosage of antipsychotics in H-EQ | 3.38 (2.39) | 3.50 (2.00) | n.s. | 3.50 (2.00) | 3.25 (2.87) | n.s. |
| H-EQ taken during interval corrected for interval duration | 856.55 (863.85) | 547.37 (548.28) | n.s. | 547.37 (548.28) | 1156.73 (1039.22) | 0.005 |
| Drugs/alcohol abuse or dependency ever before T0 (no/yes) | 19/1 | 8/8 | n.s. | 4/4 | 4/4 | n.s. |
| Drugs/alcohol abuse or dependency at T0 (no/yes) | 17/3 | 14/2 | 0.03 | 7/1 | 7/1 | n.s. |
| PANSS | | | | | | |
| Positive scale | 10.13 (2.66) | 9.00 (1.60) | n.s. | 9.00 (1.60) | 11.25 (3.11) | n.s. |
| Negative scale | 12.75 (3.15) | 13.13 (3.72) | n.s. | 13.13 (3.72) | 12.38 (2.67) | n.s. |
| General scale | 24.69 (5.34) | 23.75 (2.61) | n.s. | 23.75 (2.61) | 25.63 (7.23) | n.s. |
| GAF | 61.31 (11.61) | 58.13 (11.93) | n.s. | 58.13 (11.93) | 64.50 (11.11) | n.s. |
| CGI | 1.56 (0.63) | 1.38 (0.52) | n.s. | 1.38 (0.52) | 1.75 (0.71) | n.s. |

All differences for baseline characteristics were checked with the Pearson \(x^2\) test for nominal variables, analysis of variance for normally distributed continuous variables, and Mann-Whitney \(U\) test for not normally distributed continuous variables.

CGI indicates Clinical Global Impression; GAF, Global Assessment of Functioning; H-EQ, haloperidol equivalents; n.s., nonsignificant; PANSS, Positive and Negative Syndrome scale.
In the first slice containing both NC and putamen, segmentation of the NA started, and it ended in the slice where the boundaries for the NA were still clearly discernible. Superolaterally, the putamen and NC bordered the NA, and inferomedially, they bordered the surrounding WM.

Ten scans were duplicated and randomly intermixed with the data set to allow for an estimation of intrarater reliability using ICCs. Intraclass correlation coefficient scores were 0.99 for NC, 0.97 for NA, and 0.90 for putamen volume.

### Data Analysis

To investigate the effect of illness and antipsychotic treatment on brain volume (change) multiple linear regression analyses were performed using SPSS 15. Volumes of the total brain, cerebral GM and WM, LV, V3, nucleus accumbens, nucleus caudatus, and putamen were added as dependent variable. A group variable (patient/control) and a medication variable (on/off medication at follow-up) were added as independent variables. Age, intracranial volume, and sex were added as covariates. In case of significant group differences in (change in) basal ganglia volumes, baseline TB volume instead of the intracranial volume was added as a covariate. In addition, it was tested if baseline volume of the basal ganglia structures were correlated with volume change over time using Pearson correlations. If this were the case, baseline volume was added as a covariate.

As the patients and controls differed significantly on abuse of drugs and/or alcohol at baseline and the patient groups differed significantly on parental education, these variables were added separately as a covariate in case of significant findings. This will only be mentioned if it led to differences in the results.

The patient groups also differed significantly on duration of illness since the first start of antipsychotics, but because of the high correlations with age ($r = 0.92, P < 0.001$), adding this as a covariate will lead to the problem of multicollinearity. All statistical tests were 2-tailed. For the comparisons of volume (change) between the 2 patient groups, confidence interval, range, and median were given for significant results.

### RESULTS

#### Demographic and Clinical Comparison of Groups

Baseline characteristics were comparable between the patients and the controls and between the patient groups. There were 4 exceptions (Table 1; Data Analysis section 2.3). The 1-year relapse rate was 50% in the discontinuation group and 13% in the continuation group.

#### Illness Effect

##### Baseline

At baseline V3 and putamen, the volume of patients was significantly larger than that of the controls (Table 2). The volume at V3 remained larger after exclusion of one outlier. Correction for TB instead of intracranial volume did not change these results.

##### Change

Gray matter and NC volume changes during the interval differed significantly between patients and controls (Table 3; Fig. 1A and D). Whereas the controls showed an increase in GM and NC volumes, the patients showed decreases over time. In addition, the NA volume increase over time was more pronounced in the controls compared to that in the patients (Table 3; Fig. 1C). Furthermore, the WM volume in the patients’ group showed a larger increase over time compared to that of the controls (Table 3; Fig. 1B). The significant changes in the basal...
TABLE 2. Raw Baseline Brain Volume, Comparison Between Normal Controls (NCS) and All Patients (PTS) With Schizophrenia and Between Patients Who Continued (PTS-C) and Stopped Antipsychotic Medication (PTS-S)*

<table>
<thead>
<tr>
<th>Brain Structure</th>
<th>Normal Controls Versus Patients</th>
<th>Patients Who Discontinued Versus Patients Who Continued Antipsychotic Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline Volume NCS in mL (SD)</td>
<td>Baseline Volume PTS in mL (SD)</td>
</tr>
<tr>
<td>Total brain</td>
<td>1 181.44 (127.39)</td>
<td>1 146.84 (139.89)</td>
</tr>
<tr>
<td>Cerebral GM</td>
<td>681.49 (60.04)</td>
<td>657.41 (79.91)</td>
</tr>
<tr>
<td>Cerebral WM</td>
<td>499.95 (81.16)</td>
<td>489.43 (64.30)</td>
</tr>
<tr>
<td>Lateral ventricles</td>
<td>15.67 (12.43)</td>
<td>18.10 (8.06)</td>
</tr>
<tr>
<td>Third ventricle</td>
<td>0.65 (0.26)</td>
<td>0.99 (0.53)</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>148.07 (13.52)</td>
<td>147.52 (18.69)</td>
</tr>
<tr>
<td>N. accumbens</td>
<td>2.09 (0.45)</td>
<td>2.01 (0.45)</td>
</tr>
<tr>
<td>N. caudatus</td>
<td>7.92 (1.10)</td>
<td>7.60 (0.94)</td>
</tr>
<tr>
<td>Putamen</td>
<td>9.11 (0.73)</td>
<td>9.61 (1.60)</td>
</tr>
</tbody>
</table>

Significant findings are in bold.

*Difference between groups expressed as unstandardized regression coefficients b ± SE (b) corrected for sex, age, and intracranial volume, in which b represents the corrected volume difference in milliliters.

TABLE 3. Raw Change in Brain Volume Over 1 Year, Comparison Between All Patients With Schizophrenia and Normal Controls and Between Patients Who Continued (PTS-C) and Stopped Antipsychotic Medication (PTS-S)*

<table>
<thead>
<tr>
<th>Brain Structure</th>
<th>Volume Change NCS in mL (SD)</th>
<th>Volume Change PTS in mL (SD)</th>
<th>b</th>
<th>SE (b)</th>
<th>t df = 31</th>
<th>P</th>
<th>Volume Change PTS-S in mL (SD)</th>
<th>Volume Change PTS-C in mL (SD)</th>
<th>b</th>
<th>SE (b)</th>
<th>t df = 31</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total brain</td>
<td>7.98 (12.15)</td>
<td>5.77 (17.75)</td>
<td>0.12</td>
<td>7.12</td>
<td>0.00</td>
<td>0.99</td>
<td>9.73 (19.8)</td>
<td>1.80 (15.70)</td>
<td>−10.13</td>
<td>8.51</td>
<td>−2.63</td>
<td>0.04</td>
</tr>
<tr>
<td>Cerebral GM</td>
<td>7.35 (19.72)</td>
<td>−7.17 (13.92)</td>
<td>−16.02</td>
<td>7.50</td>
<td>−2.14</td>
<td>0.04</td>
<td>−9.73 (14.6)</td>
<td>−6.61 (13.63)</td>
<td>3.97</td>
<td>8.95</td>
<td>0.44</td>
<td>0.66</td>
</tr>
<tr>
<td>Cerebral WM</td>
<td>0.63 (17.58)</td>
<td>12.94 (17.27)</td>
<td>18.05</td>
<td>7.32</td>
<td>2.46</td>
<td>0.02</td>
<td>19.46 (15.2)</td>
<td>6.41 (17.67)</td>
<td>−12.74</td>
<td>8.75</td>
<td>−1.46</td>
<td>0.16</td>
</tr>
<tr>
<td>Lateral ventricles</td>
<td>0.07 (1.05)</td>
<td>−0.11 (0.90)</td>
<td>−0.43</td>
<td>0.43</td>
<td>−1.00</td>
<td>0.33</td>
<td>−0.38 (0.71)</td>
<td>0.16 (1.04)</td>
<td>0.55</td>
<td>0.52</td>
<td>1.07</td>
<td>0.30</td>
</tr>
<tr>
<td>Third ventricle</td>
<td>0.00 (0.08)</td>
<td>−0.01 (0.10)</td>
<td>−0.05</td>
<td>0.04</td>
<td>−1.46</td>
<td>0.15</td>
<td>−0.06 (0.07)</td>
<td>0.03 (0.12)</td>
<td>0.08</td>
<td>0.04</td>
<td>1.88</td>
<td>0.07</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>1.05 (2.89)</td>
<td>0.44 (2.70)</td>
<td>0.66</td>
<td>1.17</td>
<td>0.57</td>
<td>0.58</td>
<td>1.68 (2.22)</td>
<td>−0.80 (2.70)</td>
<td>−2.67</td>
<td>1.40</td>
<td>−1.91</td>
<td>0.07</td>
</tr>
<tr>
<td>N. accumbens</td>
<td>0.05 (0.14)</td>
<td>0.01 (0.14)</td>
<td>−0.12</td>
<td>0.06</td>
<td>−2.07</td>
<td>0.05</td>
<td>−0.07 (0.11)</td>
<td>0.08 (0.13)</td>
<td>0.14</td>
<td>0.07</td>
<td>2.12</td>
<td>0.04</td>
</tr>
<tr>
<td>N. caudatus</td>
<td>0.04 (0.21)</td>
<td>−0.04 (0.21)</td>
<td>−0.19</td>
<td>0.09</td>
<td>−2.23</td>
<td>0.03</td>
<td>−0.13 (0.22)</td>
<td>0.06 (0.15)</td>
<td>0.19</td>
<td>0.10</td>
<td>1.89</td>
<td>0.07</td>
</tr>
<tr>
<td>Putamen</td>
<td>−0.17 (0.37)</td>
<td>0.28 (0.65)</td>
<td>0.02</td>
<td>0.17</td>
<td>0.13</td>
<td>0.89</td>
<td>−0.11 (0.27)</td>
<td>0.67 (0.70)</td>
<td>0.77</td>
<td>0.21</td>
<td>3.72</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Significant findings are in bold.

*Difference between groups expressed as unstandardized regression coefficients b ± SE (b) corrected for sex, age, and intracranial volume, in which b represents the corrected volume difference in milliliters.
ganglia remained significant after correction for the baseline TB volume and the baseline volume of the structure concerned. However, after exclusion of the largest outlier in the patients, the difference in the NA change was not significant ($P = 0.18$), and after correction for having a positive history of alcohol or drug abuse or dependency, the difference in the NA change was trend-level significant ($P = 0.06$).

**Medication Effect**

The 2 patient groups did not differ significantly on any of the volumes at baseline except for the putamen volume (Table 2; $b = -1.49$; 95% CI, $-2.23$ to $-0.74$); discontinuation group: range (8.52–13.12), median (10.07); continuation group: range (6.75–11.08), median (8.88).

Over time, a decrease in NA and putamen volumes was found in patients who discontinued medication, whereas increases were found in the patients who continued their antipsychotics (Table 3; Fig. 2, A and B; NA: $b = 0.14$; 95% CI, 0.01–0.28; discontinuation group: range [$-0.32$ to 0.02], median [$-0.04$]; continuation group: range [$-0.09$ to 0.33], median [$-0.07$]; putamen: $b = 0.77$; 95% CI, 0.35–1.20; discontinuation group: range [$-0.53$ to 0.21], median [$-0.03$]; continuation group: range [$-0.29$ to 1.93], median [0.49]). Correction for TB volume did not change these findings. However, after exclusion of the largest outlier in the patients, the difference in the NA changes was no longer significant ($P = 0.12$).

**DISCUSSION**

This study examined the effect of discontinuation of atypical antipsychotic medication on brain volume change during a 1-year interval in remitted and stable patients with first-episode schizophrenia. We replicated earlier findings of excessive decrease in cerebral GM volume in patients relative to controls. In addition, our results suggest that discontinuation or continuation of atypical antipsychotics does not influence GM volume change.

---

**FIGURE 1.** One-year (raw) volume change in controls and patients for cerebral GM (A), cerebral white matter (B), nucleus accumbens (C), and nucleus caudate (D).

**FIGURE 2.** One-year (raw) nucleus accumbens (A) and putamen (B) volume change in patients who either stopped or continued antipsychotic treatment before a second MRI scan. Note the differences in range of the y-axis.
in patients. If anything, cerebral GM volume decrease over time seemed more pronounced in the patients who discontinued than in those who continued antipsychotic medication, although this difference was not significant. Our results suggest that the excessive reduction of GM volume occurs irrespective of atypical antipsychotic treatment continuation or discontinuation. This might indicate that the excessive loss of GM volume in patients with schizophrenia cannot be explained by the intake of atypical antipsychotic medication.

To date, only a limited number of longitudinal studies have been done that looked directly at the influence of atypical antipsychotic treatment on brain volume in a controlled manner. This is especially the case if one excludes studies in which the prestudy treatment was unknown and consisted of both atypical and typical antipsychotics, or where patients were analyzed together independently of being antipsychotic naive, or not, before the study. One randomized study identified GM loss after 1 year of treatment with haloperidol compared to olanzapine. Unfortunately, it was not mentioned what type of antipsychotics (typical/atypical) the patients used before the start of the study medication. Together, these findings suggest that atypical antipsychotics might prevent the loss of GM tissue. Indeed, in a large longitudinal study in a sample of both first-episode and chronically ill patients, cumulative intake of atypical medication was associated with less loss of GM tissue.

That GM tissue loss is most likely associated with the effects of the illness, and is not a consequence of atypical antipsychotic medication intake, is also supported by evidence that cerebral GM deficits in patients seem to be present before the start of antipsychotic medication, or even before the start of the first symptoms. However, some studies report no differences between normal controls and medication-naive patients.

In contrast to our findings in humans, a randomized study in Macaque monkeys found that chronic treatment with atypical medication (n = 6, for 1.2 years) and typical (n = 6, for 2.2 years) antipsychotics resulted in a reduction of parietal GM volume compared with placebo. However, it is difficult to extrapolate these regional postmortem animal findings to those occurring in vivo in the brains of patients with schizophrenia.

Antipsychotics may exert their effect in focal areas of the brain. Here, we focused on the basal ganglia. At baseline, all patients were on atypical antipsychotic medication. The patients discontinuing atypical antipsychotics seemed to decrease in NA and putamen volumes over time. This is of particular interest inasmuch as the putamen volume seemed to increase in the patients compared to the controls at baseline. Moreover, the 2 patient groups did not differ on baseline brain volumes, except for the putamen, which was larger in the patients who discontinued their antipsychotic regimen compared to the patients who continued their antipsychotic medication. Outcome of the illness might be a possible explanation for this, as Buchsbaum et al identified a larger putamen in patients with good outcome of schizophrenia in comparison to those with a poor outcome and healthy controls. Indeed, the patients who stopped tolerated tapering and were able to not use medication without experiencing a relapse for a certain period of time. Whether this would have been the case in those that continued their antipsychotics is unknown.

It might be that the increase in putamen volume at baseline in the patients relative to the controls is an effect of taking atypical antipsychotic medication (although this cannot be tested in our study, but see Glenthoj et al). If this were the case, our findings suggest that discontinuation reverses the effects of atypical medication, at least in the putamen and possibly, to some extent, in the NA.

Indeed, starting atypical antipsychotics in antipsychotic-naive patients resulted in volume increases in the NC and putamen 22 compared to baseline or compared to the controls, although some studies found no volume changes. In contrast, starting atypical antipsychotics after discontinuing typical antipsychotic medication has been associated with caudate and putamen volume reductions, whereas other studies found no caudate or putamen volume change. These data imply that the consequences of atypical medication are dependent on the state of the brain, being medication-naive or being on typical medication.

Suggestive evidence was found for an excessive increase over time in cerebral WM volume in the patients compared to the controls, which, in the patients, did not seem to be influenced by either continuation or discontinuation of antipsychotics. Cerebral WM volume in the antipsychotic-naive patients was reported to be similar to the healthy controls but for decreased WM, see Chua et al. Although the initiation of atypical antipsychotics in antipsychotic-naive or antipsychotic-free schizophrenia did not result in WM volume changes, WM volume did decrease significantly in haloperidol-treated patients whose treatment was changed to clozapine.

Strengths and Limitations

Studies like this one are complicated to carry out, resulting in a small number of included patients. Consequently, type II errors cannot be ruled out. To our knowledge, this is the first MRI study that compared brain volume change between patients who discontinued or continued atypical antipsychotic medication. Therefore, we are convinced that, despite the small sample size, it is important to present these data. In addition, this serves as the rationale for not applying a correction for multiple testing. Most of our findings would not have survived such a correction.

Half of the patients in this study were randomized to continuation (n = 4) or discontinuation (n = 4). In the continuation group, the remaining 4 patients chose to continue their medication because of fear of relapse, which is a sign of good insight. In contrast, in the discontinuation group, 4 patients decided to stop their antipsychotic treatment despite risk of relapse. Because insight is a predictor of good outcome, the continuation group might have consisted of patients with a better outcome than the discontinuation group. However, all patients were clinically stable enough to allow for discontinuation at inclusion in the study.

In this study, the patients used olanzapine, risperidone, or quetiapine, which are grouped among the atypical antipsychotics and have less binding potential for the D2 receptor than typical antipsychotics. However, risperidone is known to have a more firm grip on the D2 receptor than the second-generation antipsychotics. This differential effect of binding potential for the 3 antipsychotics used in this study might have diluted the volume changes in the discontinuation group in the basal ganglia structures.

The exclusion of more severe patients (at risk or with history of suicide, and abandonment of previous treatment) and the inclusion of patients with a priori better prognosis than schizophrenia such as schizophrenia affective disorder and schizophreniform disorder, made this sample one with a better prognosis than the general population of first psychotic episodes, as indicated by the values of the PANSS, the Global Assessment of Functioning, and the Clinical Global Impression at baseline. This is a
consequence of the design of the study, as guidelines offer the psychiatrist the possibility to discontinue antipsychotic medication only in remitted and stable patients with first-episode schizophrenia.28

CONCLUSIONS

We confirmed earlier findings of GM volume decrements in patients with schizophrenia in comparison to healthy controls. Our main conclusion is that the excessive cerebral GM volume decrease found in patients with schizophrenia is unlikely to be explained by atypical antipsychotic treatment. However, the increase in putamen volume at baseline seems to be (at least partly) a medication effect as putamen (and also nucleus accumbens) volume decreased in patients after discontinuation with atypical antipsychotics.

AUTHOR DISCLOSURE INFORMATION

The authors declare no relevant conflicts of interest.

REFERENCES


